



**Figure S1** Angiostamp800, Bevacizumab-IRDye 800CW, and ICG fluorescence detectability. Fluorescence signals of 10 μL of decreasing concentrations of Angiostamp800, Bevacizumab-IRDye 800CW and ICG diluted in murine plasma. The highest concentrations of Angiostamp800 and ICG underwent fluorescence quenching. Fluorescence detection was linear for probe concentrations that provided significantly higher specific signals than background (14 nmol.L<sup>-1</sup> for Bevacizumab-IRDye 800CW, 46 nmol.L<sup>-1</sup> for Angiostamp800 and 170 nmol.L<sup>-1</sup> for ICG).